164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355

D.W. Cescon, P. Schmid,H.S. Rugo,S-A. Im,M. Md Yusof, C.E. Gallardo, O. Lipatov, C.H. Barrios,J.M. Perez Garcia, H. Iwata, N. Masuda, M.A. Torregroza Otero, E. Gokmen,S. Loi, A. Haiderali, X. Zhou, Z. Guo, A. Martin Nguyen,J. Cortés

Annals of Oncology（2022）

引用 0|浏览2

暂无评分

摘要

KEYNOTE-355 (NCT02819518) evaluated pembro + chemo vs pbo + chemo in previously untreated patients (pts) with locally recurrent inoperable or metastatic TNBC. Pembro + chemo improved the PFS and OS in pts with PD-L1 combined positive score (CPS) ≥10 disease. We present results for patient-reported outcome (PRO) measures among pts with PD-L1 CPS ≥10.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要